Announcement

Collapse

WELCOME TO OUR NEW HOME!

Hello MSWorld Members,

Welcome to our new home! We hope you love it as much as we do!


we promise.

to offer current and relevant information.

to grow a community built on positive and affirming support.

to showcase member creativity.

to provide safe chat rooms.

to provide well moderated forums.


we believe that what we give as a community comes back to us.

welcome to MSWorld on this journey through a different lens. together. we are msworld.
we are. community.


We appreciate your understanding as we finalize our new home. Our arcade is still currently under construction and won’t be available for a while. Thank you for your patience while we prepare a new and improved arcade for you.

enjoy our new home.

support reimagined.
See more
See less

Gilenya Rebound?

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Gilenya Rebound?

    Study Identifies MS Patients at Risk of Severe Disease Reactivation After Gilenya Is Discontinued

    Fingolimod withdrawal may trigger the return of pretreatment disease activity. It is difficult to identify patients at risk of disease reactivation. We compared the demographic and clinical features of patients experiencing severe disease reactivation (SDR) after fingolimod cessation with those of patients who did not.

    https://insights.ovid.com/crossref?a...01801000-00003

    #2
    Marco,thanks for this info. Sounds like neuros need to figure out a safe gilenya discontinuation method so high risk patients don't end up worse off when switching to a new therapy.

    Comment

    Working...
    X